Sionna Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Sionna's SION-719 failed to meet its key efficacy endpoint in the PreciSION CF Phase 2a trial, showing only -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7) when added to Trikafta in 15 CF patients. The company will not advance SION-719 as an add-on to standard of care. SION-451 dual combinations (preferred: SION-451 + SION-2222) achieved safety and PK objectives in a 120-subject Phase 1 healthy volunteer trial; next steps are under evaluation. Sionna ended Q2 2026 with $268.3M in cash and plans capital-preservation measures.
Why this rating
Lead program failure eliminates a major pipeline asset and forces strategy pivot; cash burn accelerates under preservation mode. Material relative to $342M market cap but company retains dual-combination backup.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.